MY161656A - Therapeutic use of diaminophenothiazines - Google Patents
Therapeutic use of diaminophenothiazinesInfo
- Publication number
- MY161656A MY161656A MYPI2010001396A MYPI2010001396A MY161656A MY 161656 A MY161656 A MY 161656A MY PI2010001396 A MYPI2010001396 A MY PI2010001396A MY PI2010001396 A MYPI2010001396 A MY PI2010001396A MY 161656 A MY161656 A MY 161656A
- Authority
- MY
- Malaysia
- Prior art keywords
- diaminophenothiazines
- therapeutic use
- relates
- prophylaxis
- treatments
- Prior art date
Links
- KPYHKEZPEDJERZ-UHFFFAOYSA-N 10h-phenothiazine-1,2-diamine Chemical class C1=CC=C2NC3=C(N)C(N)=CC=C3SC2=C1 KPYHKEZPEDJERZ-UHFFFAOYSA-N 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 238000011282 treatment Methods 0.000 abstract 2
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 230000001149 cognitive effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 230000002489 hematologic effect Effects 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96054407P | 2007-10-03 | 2007-10-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY161656A true MY161656A (en) | 2017-04-28 |
Family
ID=40220337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2010001396A MY161656A (en) | 2007-10-03 | 2008-10-01 | Therapeutic use of diaminophenothiazines |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US9149481B2 (OSRAM) |
| EP (2) | EP2954932B1 (OSRAM) |
| JP (1) | JP5592261B2 (OSRAM) |
| CN (1) | CN101883567B (OSRAM) |
| AU (1) | AU2008306688B2 (OSRAM) |
| BR (1) | BRPI0818182B1 (OSRAM) |
| CA (2) | CA3027974C (OSRAM) |
| DK (2) | DK2954932T3 (OSRAM) |
| ES (2) | ES2546819T3 (OSRAM) |
| HR (1) | HRP20151006T1 (OSRAM) |
| HU (1) | HUE025199T2 (OSRAM) |
| MY (1) | MY161656A (OSRAM) |
| PL (2) | PL2954932T3 (OSRAM) |
| PT (2) | PT2205245E (OSRAM) |
| SI (2) | SI2954932T1 (OSRAM) |
| WO (1) | WO2009044127A1 (OSRAM) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY143757A (en) | 2006-03-29 | 2011-07-15 | Wista Lab Ltd | 3,7-diamond-10h-phenothiazine salts and their use |
| SI2954932T1 (sl) * | 2007-10-03 | 2019-01-31 | Wista Laboratories Ltd. | Terapevtska uporaba diaminofenotiazinov |
| US8785434B2 (en) | 2010-04-30 | 2014-07-22 | Prosetta Antiviral Inc. | Antiviral compounds |
| US9192611B2 (en) | 2010-11-30 | 2015-11-24 | Wista Laboratories Ltd. | Formulations comprising methylthioninium chloride |
| CA2826286C (en) | 2011-01-31 | 2021-09-21 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| SG192666A1 (en) | 2011-02-11 | 2013-09-30 | Wista Lab Ltd | Phenothiazine diaminium salts and their use |
| CN102690244A (zh) * | 2011-03-22 | 2012-09-26 | 中国科学院上海生命科学研究院 | 调节α-突触核蛋白积聚的物质及其制药用途 |
| EP2699241B1 (en) | 2011-04-20 | 2016-07-27 | Prosetta Antiviral Inc. | Antiviral compounds |
| US20130315825A1 (en) * | 2012-05-03 | 2013-11-28 | Washington University | Tricyclic heteroaromatic compounds as alpha-synuclein ligands |
| CN103864717B (zh) * | 2014-04-04 | 2015-11-11 | 山东理工大学 | 一种针状亚甲基白晶体的制备方法 |
| CN103923036B (zh) * | 2014-04-24 | 2015-09-16 | 山东理工大学 | 一种棒状亚甲基蓝晶体的制备方法 |
| CN105541756B (zh) * | 2015-12-17 | 2018-02-09 | 陕西方舟制药有限公司 | 一种制备1‑(3，7‑双二甲氨基‑吩噻嗪‑10‑基)乙酮的方法 |
| EP3487505B1 (en) | 2016-07-25 | 2023-05-03 | WisTa Laboratories Ltd. | Administration and dosage of diaminophenothiazines |
| GB201614834D0 (en) | 2016-09-01 | 2016-10-19 | Wista Lab Ltd | Treatment of dementia |
| EP4364801B1 (en) | 2018-07-26 | 2025-11-12 | TauRx Therapeutics Management Ltd. | Optimised dosage of diaminophenothiazines in populations |
| WO2020201828A1 (en) | 2019-04-05 | 2020-10-08 | Tauc3 Biologics Limited | Anti-tauc3 antibodies and uses thereof |
| GB201909493D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Therapeutic interactions |
| GB201909454D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Enhancers |
| GB201909506D0 (en) | 2019-07-02 | 2019-08-14 | Wista Lab Ltd | Synaptopathies |
| CN111956245A (zh) * | 2020-08-27 | 2020-11-20 | 复旦大学附属肿瘤医院 | 术后认知功能障碍预防评估方法，系统和装置 |
| WO2023232764A1 (en) | 2022-05-31 | 2023-12-07 | Wista Laboratories Ltd. | Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds |
| AU2023346900A1 (en) | 2022-09-21 | 2025-04-10 | TauRx Therapeutics Management Ltd | Novel formulations and vehicles |
| WO2024163665A1 (en) * | 2023-01-31 | 2024-08-08 | Unlearn.AI, Inc. | Systems and methods for prognostic covariate adjustment in logistic regression for randomized controlled trial design |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9022788D0 (en) * | 1990-10-19 | 1990-12-05 | Cortecs Ltd | Pharmaceutical formulations |
| DE4140192C2 (de) * | 1991-12-05 | 1996-02-29 | Alfatec Pharma Gmbh | Sol-gesteuerte Thermokolloidmatrix auf Gelatinebasis für perorale Retardformen |
| GB9506197D0 (en) * | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| US5972389A (en) | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
| GB9710699D0 (en) | 1997-05-24 | 1997-07-16 | Danbiosyst Uk | Gastro-retentive controlled release system |
| GB0017060D0 (en) * | 2000-07-11 | 2000-08-30 | Hunter Fleming Ltd | Production, stabilisation and use of reduced forms of pharmaceutical compounds |
| GB0100119D0 (en) * | 2001-01-03 | 2001-02-14 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| GB0101049D0 (en) * | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| GB0106953D0 (en) | 2001-03-20 | 2001-05-09 | Univ Aberdeen | Neufofibrillary labels |
| US7410965B2 (en) * | 2002-05-29 | 2008-08-12 | Gruenenthal Gmbh | Delayed release pharmaceutical composition containing 1-dimethyl-amino-3-(3-methoxyphenyl)-2-methyl-pentan-3-ol |
| GB0322756D0 (en) | 2003-09-29 | 2003-10-29 | Univ Aberdeen | Methods of chemical synthesis |
| JP5186212B2 (ja) * | 2004-09-23 | 2013-04-17 | ウィスタ ラボラトリーズ リミテッド | メチルチオニニウム塩化物（ｍｔｃ）などのジアミノフェノチアジニウム化合物を化学合成および精製する方法 |
| WO2006091728A2 (en) * | 2005-02-24 | 2006-08-31 | The Trustees Of The University Of Pennsylvania | Microtubule stabilizing compounds and methods of their use |
| US20070116757A1 (en) | 2005-11-08 | 2007-05-24 | Collegium Pharmaceutical, Inc. | Methylene Blue Derivatives |
| MY143757A (en) | 2006-03-29 | 2011-07-15 | Wista Lab Ltd | 3,7-diamond-10h-phenothiazine salts and their use |
| CN101460157B (zh) * | 2006-03-29 | 2015-09-02 | 维斯塔实验室有限公司 | 蛋白聚集抑制剂 |
| AU2007274057B2 (en) | 2006-07-11 | 2012-12-13 | TauRx Therapeutics Management Ltd | Methods of synthesis and/or purification of diaminophenothiazinium compounds |
| CA2690746C (en) * | 2007-06-19 | 2018-01-02 | Wista Laboratories Ltd | Phenothizine compounds for treating mild cognitive impairment |
| SI2954932T1 (sl) * | 2007-10-03 | 2019-01-31 | Wista Laboratories Ltd. | Terapevtska uporaba diaminofenotiazinov |
-
2008
- 2008-10-01 SI SI200832022T patent/SI2954932T1/sl unknown
- 2008-10-01 CN CN2008801190788A patent/CN101883567B/zh active Active
- 2008-10-01 PT PT88064654T patent/PT2205245E/pt unknown
- 2008-10-01 DK DK15161198.5T patent/DK2954932T3/en active
- 2008-10-01 AU AU2008306688A patent/AU2008306688B2/en active Active
- 2008-10-01 EP EP15161198.5A patent/EP2954932B1/en active Active
- 2008-10-01 BR BRPI0818182-9A patent/BRPI0818182B1/pt active IP Right Grant
- 2008-10-01 PL PL15161198T patent/PL2954932T3/pl unknown
- 2008-10-01 HU HUE08806465A patent/HUE025199T2/en unknown
- 2008-10-01 MY MYPI2010001396A patent/MY161656A/en unknown
- 2008-10-01 WO PCT/GB2008/003315 patent/WO2009044127A1/en not_active Ceased
- 2008-10-01 PL PL08806465T patent/PL2205245T3/pl unknown
- 2008-10-01 EP EP08806465.4A patent/EP2205245B1/en active Active
- 2008-10-01 CA CA3027974A patent/CA3027974C/en active Active
- 2008-10-01 HR HRP20151006TT patent/HRP20151006T1/hr unknown
- 2008-10-01 DK DK08806465.4T patent/DK2205245T3/en active
- 2008-10-01 US US12/681,511 patent/US9149481B2/en active Active
- 2008-10-01 ES ES08806465.4T patent/ES2546819T3/es active Active
- 2008-10-01 ES ES15161198T patent/ES2701089T3/es active Active
- 2008-10-01 CA CA2701075A patent/CA2701075C/en active Active
- 2008-10-01 SI SI200831497T patent/SI2205245T1/sl unknown
- 2008-10-01 PT PT15161198T patent/PT2954932T/pt unknown
- 2008-10-01 JP JP2010527519A patent/JP5592261B2/ja active Active
-
2015
- 2015-09-25 US US14/866,035 patent/US10188658B2/en active Active
-
2019
- 2019-01-15 US US16/248,746 patent/US20190151329A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY161656A (en) | Therapeutic use of diaminophenothiazines | |
| TR201819564T4 (tr) | Cmt ve ilgili bozuklukların tedavisi için yeni terapötik yaklaşımlar. | |
| MX2013011908A (es) | Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank. | |
| UA108198C2 (uk) | Заміщені 2-ацетамідо-5-арил-1,2,4-триазолони та їх застосування | |
| PH12013502620A1 (en) | Novel inhibitor compounds of phosphodiesterase type 10a | |
| IN2012DN02081A (OSRAM) | ||
| AU2011328009A8 (en) | Compounds and methods for treating pain | |
| PH12012500916B1 (en) | Treatments for gastrointestinal disorders | |
| MX2010002732A (es) | Inhibidores de f1f0-atpasa y metodos relacionados. | |
| MX2010007490A (es) | Preparacion de derivados de sulfamida. | |
| MX2012000034A (es) | Metodos para el tratamiento o la prevencion de la fatiga. | |
| MY198422A (en) | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same | |
| GB2463833A (en) | Methods and compositions for the treatment of neurological disorders | |
| MX2011010782A (es) | Compuestos agonistas del receptor 5-ht4 para el tratamiento de trastornos cognitivos. | |
| MX2009010407A (es) | Derivados fluorados de deferiprona. | |
| MX2009006327A (es) | Compuestos heterociclicos y metodos de uso de los mismos. | |
| MX2011013032A (es) | Inhibidores de fosfatidilinositol 3-cinasa. | |
| MY150931A (en) | Substituted oxazolidinones and their use | |
| EA201171172A1 (ru) | Применение в терапии производных хиназолиндиона | |
| PH12014500250A1 (en) | Substituted 3-(biphenyl-3-yl)-4 -hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one | |
| MX2013002121A (es) | Quinolina-3-carboxamidas sustituidas como moduladores de kcnq2/3. | |
| MX2013002118A (es) | 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3. | |
| ATE475651T1 (de) | Aryl-substituierte heterozyklen und ihre verwendung | |
| MX343366B (es) | Peptidos de nd2 y metodos de tratamiento de enfermedad neurologica. | |
| MX2015005733A (es) | Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad. |